



New Insights on Drug Design, Delivery and Targeting in Neurodegeneration

Guest Editors:

Dr. Renata Silva

1. Associate Laboratory i4HB—
Institute for Health and
Bioeconomy, Faculty of
Pharmacy, University of Porto,
Porto, Portugal

2. UCIBIO—Applied Molecular
Biosciences Unit, Laboratory of
Toxicology, Department of
Biological Sciences, Faculty of
Pharmacy, University of Porto,
Porto, Portugal

Dr. Daniel José Barbosa

1. Associate Laboratory i4HB—
Institute for Health and
Bioeconomy, University Institute
of Health Sciences—CESPU,
4585-116 Gandra, Portugal

2. UCIBIO—Applied Molecular
Biosciences Unit, Translational
Toxicology Research Laboratory,
University Institute of Health
Sciences (IH-TOXRUN, IUCS-
CESPU), 4585-116 Gandra,
Portugal

Message from the Guest Editors

Dear Colleagues,

Neurodegenerative diseases represent a heterogeneous group of disorders characterized by progressive degeneration and death of neuronal populations. This problem is even more fundamental as the available therapies remain fairly limited and mainly focusing on symptoms relief. Thus, the development of novel drug candidates, based on state-of-the-art chemistry methodologies and/or sparsely explored chemical substances, could help to identify lead compounds with potential pharmaceutical application. On the other hand, the lack of drug efficacy in neurodegeneration treatment comes from a compromised drug delivery to their target sites. Thus, the development of cutting-edge drug delivery systems and approaches would add substantial advance in neurodegeneration treatment. In this special issue we are interested in reviews and original articles describing novel chemical design-based drug candidates and improved delivery systems to target sites with potential to deal with neurodegeneration.

drug design and discovery

drug delivery

drug targeting

neurodegeneration

new therapeutic strategies

in vitro models of neurodegeneration

Deadline for manuscript
submissions:



July 2023)

mdpi.com/si/111102

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
[X@MDPIpharma](https://twitter.com/MDPIpharma)